The build-up to Dementia Awareness Week this year is unlike any before – donanemab is the second drug in a year to succeed in clinical trials, suggesting an end is in sight for Alzheimer’s.  The results from the drugs clinical trial, which were announced yesterday, discovered Donanemab slowed cognitive decline by 35% and slowed progression … Continue reading Beginning of the end of Alzheimer’s? New drug slows the disease by a third